NanoViricides, Inc. (NYSE American: NNVC) announced it is awaiting regulatory approval to begin a Phase II clinical trial of its NV-387 Oral Gummies for the treatment of Bundibugyo ebolavirus in the Democratic Republic of the Congo (DRC). The company submitted an application to the local regulatory agency and has secured financing to support the study, which is designed to evaluate the oral antiviral in response to the ongoing Ebola outbreak. Currently, no approved treatment or vaccine exists for the Bundibugyo strain.
According to the company, NV-387 is the only orally administered Ebola treatment candidate currently under consideration for clinical testing. NanoViricides believes its broad-spectrum antiviral mechanism could offer advantages over infusion-based therapies in resource-limited outbreak settings. The company noted that sufficient quantities of the drug are already in the DRC to support the planned Ebola study, pending regulatory approval.
The announcement highlights the potential for NV-387 to address a critical unmet need in the ongoing outbreak. The Bundibugyo ebolavirus is one of several Ebola virus species, and the lack of approved treatments or vaccines for this strain underscores the importance of developing new therapies. NanoViricides' oral gummy formulation could simplify administration and improve patient compliance, especially in areas with limited healthcare infrastructure.
NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is a broad-spectrum antiviral being developed for respiratory viral infections, MPOX, smallpox, and measles, among others. The company's platform technology is based on the TheraCour nanomedicine technology, which it licenses from TheraCour Pharma, Inc. For more information, visit the company's newsroom at https://ibn.fm/NNVC.
The ongoing Ebola outbreak in the DRC has prompted global health authorities to seek effective treatments. If approved, the Phase II trial could provide critical data on the safety and efficacy of NV-387 against the Bundibugyo strain. The company's ability to have drug supplies pre-positioned in the DRC demonstrates preparedness for rapid deployment.
Investors and public health officials will be watching for the regulatory decision, as a positive outcome could pave the way for further development and potential emergency use authorization. The oral formulation also distinguishes NV-387 from existing intravenous therapies, which require cold chain logistics and trained medical personnel for administration.
For more details on the press release, visit https://ibn.fm/t1kLC.
